These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37317885)

  • 1. The role of biomarkers in stage III non-small cell lung cancer.
    Rosell R; González-Cao M; Ito M; Santarpia M; Aguilar A; Codony-Servat J
    Expert Rev Respir Med; 2023; 17(6):469-480. PubMed ID: 37317885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
    Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
    Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
    Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series.
    Dasari S; Komiya T
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):217-220. PubMed ID: 35092391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.
    Lebow ES; Shepherd A; Eichholz JE; Offin M; Gelblum DY; Wu AJ; Simone CB; Schoenfeld AJ; Jones DR; Rimner A; Chaft JE; Riaz N; Gomez DR; Shaverdian N
    JAMA Netw Open; 2023 Jan; 6(1):e2249591. PubMed ID: 36602799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
    Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
    Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial.
    Filippi AR; Agustoni F; Arcangeli S; Cortinovis D; Ferrari A; Cicognini D; Saddi J; Klersy C; Pedrazzoli P; Malapelle U; Grossi F
    Clin Lung Cancer; 2023 May; 24(3):e122-e125. PubMed ID: 36759266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
    BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
    Puri S; Saltos A; Perez B; Le X; Gray JE
    Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
    Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
    Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
    Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
    Schmid S; Garcia M; Cheng S; Zhan L; Chotai S; Balaratnam K; Khan K; Patel D; Catherine Brown M; Sachdeva R; Xu W; Shepherd FA; Sacher A; Leighl NB; Bradbury P; Moriarty P; Sara Kuruvilla M; Liu G
    Lung Cancer; 2022 Apr; 166():58-62. PubMed ID: 35183992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.
    Myall NJ; Das M
    Clin Chest Med; 2020 Jun; 41(2):211-222. PubMed ID: 32402357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
    Catania C; Filippi AR; Sangalli C; Piperno G; Russano M; Greco C; Scotti V; Proto C; Bennati C; Di Pietro Paolo M; Platania A; Olmetto E; Agustoni F; Teodorani N; Agbaje V; Russo A
    Crit Rev Oncol Hematol; 2023 Oct; 190():104108. PubMed ID: 37633350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.